nominally significantP = 0.02
Table 3 shows that there was nominally significant evidence that ever use of HRT was associated with an increased risk of breast cancer among all women (OR 1.86; 95% CI 1.11 to 3.12; P = 0.02).
Table 3 shows that there was nominally significant evidence that ever use of HRT was associated with an increased risk of breast cancer among all women (OR 1.86; 95% CI 1.11 to 3.12; P = 0.02).
There was no evidence of deviation from Hardy–Weinberg equilibrium in controls ( P = 0.95), but in cases there was marginally significant evidence of such deviation, with a deficiency of heterozygotes (565 observed versus 605.3 expected; P = 0.02).
The only associations near statistical significance were that postmenopausal women with A 1 / A 1 (wild-type) genotype had an increased risk of breast cancer if they had ever used hormone replacement therapy (OR 2.40, 95% CI 1.0 to 5.7; P = 0.05) and if they had menopause after age 47 years (OR 2.59, 95% CI 1.0 to 7.0; P = 0.06).